Search research articles
Contact Us
Filters
Showing results (111-120 of 123) with videos related to
Page
of 13
Sort By:
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi = Chinese Journal of Schistosomiasis Control
|
January 16, 2023
[Epidemiological investigation on a visceral leishmaniasis case in Zhengzhou City of Henan Province]
C Y Yang, X M Zhao, D L Lu, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology
|
March 9, 2023
[Analysis of the diagnostic performance of MRI Liver Imaging Reporting and Data System version 2018 for intrahepatic parenchymal substantial lesions ≤3.0 cm]
B R Li, X M Zhao, J X Zou, et al.
Circulation Research
|
December 7, 2017
TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year Analysis
Jay H Traverse, Timothy D Henry, Carl J Pepine, et al.
American Heart Journal
|
September 7, 2016
Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial
Aruni Bhatnagar, Roberto Bolli, Brian H Johnstone, et al.
Circulation Research
|
November 20, 2014
Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial
Robert C Schutt, Barry H Trachtenberg, John P Cooke, et al.
Cell Transplantation
|
November 22, 2015
Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial
Doris A Taylor, Emerson C Perin, James T Willerson, et al.
American Heart Journal
|
August 10, 2010
Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design
James T Willerson, Emerson C Perin, Stephen G Ellis, et al.
Texas Heart Institute Journal
|
September 17, 2010
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction
Jay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.
American Heart Journal
|
August 25, 2009
Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction
Jay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.
Circulation Research
|
August 20, 2014
Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes
Christopher R Cogle, Elizabeth Wise, Amy M Meacham, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 123) with videos related to
Sort By:
Page
of 13
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi = Chinese Journal of Schistosomiasis Control
|
January 16, 2023
[Epidemiological investigation on a visceral leishmaniasis case in Zhengzhou City of Henan Province]
C Y Yang, X M Zhao, D L Lu, et al.
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology
|
March 9, 2023
[Analysis of the diagnostic performance of MRI Liver Imaging Reporting and Data System version 2018 for intrahepatic parenchymal substantial lesions ≤3.0 cm]
B R Li, X M Zhao, J X Zou, et al.
Circulation Research
|
December 7, 2017
TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year Analysis
Jay H Traverse, Timothy D Henry, Carl J Pepine, et al.
American Heart Journal
|
September 7, 2016
Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial
Aruni Bhatnagar, Roberto Bolli, Brian H Johnstone, et al.
Circulation Research
|
November 20, 2014
Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial
Robert C Schutt, Barry H Trachtenberg, John P Cooke, et al.
Cell Transplantation
|
November 22, 2015
Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial
Doris A Taylor, Emerson C Perin, James T Willerson, et al.
American Heart Journal
|
August 10, 2010
Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design
James T Willerson, Emerson C Perin, Stephen G Ellis, et al.
Texas Heart Institute Journal
|
September 17, 2010
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction
Jay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.
American Heart Journal
|
August 25, 2009
Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction
Jay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.
Circulation Research
|
August 20, 2014
Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes
Christopher R Cogle, Elizabeth Wise, Amy M Meacham, et al.
Page
of 13